Progression of heart failure: a role for interstitial fibrosis.
about
The effect of enalapril and verapamil on the left ventricular hypertrophy and the left ventricular cardiomyocyte numerical density in rats submitted to nitric oxide inhibitionPathophysiology of Heart Failure.Silent disease progression in clinically stable heart failure.Piperine Attenuates Pathological Cardiac Fibrosis Via PPAR-γ/AKT Pathways.Large animal models of heart failure.Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes.Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy.Curcumin suppresses transforming growth factor-β1-induced cardiac fibroblast differentiation via inhibition of Smad-2 and p38 MAPK signaling pathways.Prostaglandin E2 increases cardiac fibroblast proliferation and increases cyclin D expression via EP1 receptor.Myocardial transfection with naked DNA plasmid encoding hepatocyte growth factor prevents the progression of heart failure in dogs.Effects of calorie restriction on cardioprotection and cardiovascular healthPlacental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism.Genetic Analysis of Connective Tissue Growth Factor as an Effector of Transforming Growth Factor β Signaling and Cardiac Remodeling.The role of endothelin-1 in myocarditis and inflammatory cardiomyopathy: old lessons and new insights.Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy.Placental growth factor as a protective paracrine effector in the heartNo Evidence of Myocardial Oxygen Deprivation in Nonischemic Heart Failure.Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.Darbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure.Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.Augmentation of left ventricular wall thickness with alginate hydrogel implants improves left ventricular function and prevents progressive remodeling in dogs with chronic heart failure.Cardiac fibroblasts require focal adhesion kinase for normal proliferation and migration.Baroreflex activation for the treatment of heart failure.Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure.Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure.Vascular endothelial growth factor inhibition by dRK6 causes endothelial apoptosis, fibrosis, and inflammation in the heart via the Akt/eNOS axis in db/db mice.Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart.Alterations in mitochondrial function in cardiac hypertrophy and heart failure.Cardiac myocyte-fibroblast interactions and the coronary vasculature.Cellular Interplay between Cardiomyocytes and Nonmyocytes in Cardiac Remodeling.Epigenetic balance of aberrant Rasal1 promoter methylation and hydroxymethylation regulates cardiac fibrosis.Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice.The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy.A sensitive short-term evaluation of antifibrotic effects using newly established type I collagen reporter transgenic rats.Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats.Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats.Cardiomyocytes from postinfarction failing rat hearts have improved ischemia tolerance.Pathophysiology of acute heart failure syndrome: a knowledge gap.Mechanisms and Therapeutic Targets of Cardiac Regeneration: Closing the Age Gap.Cardiac diastolic dysfunction in conscious dogs with heart failure induced by chronic coronary microembolization.
P2860
Q28343881-9B27C88A-DCCF-4508-82EA-AAA389D08954Q30315815-9041664A-6AA6-40E4-87FB-7E830952DF98Q33578212-62FD7901-BE88-40E7-9537-6A68D3FEC423Q33603596-38D9AEBC-17BD-412C-A23C-C108E6F5AC75Q33951256-C18BF9FC-AF08-4DD8-B649-49A9B989E53DQ33998649-9F8A2339-07A9-41CC-A91A-4D5188564241Q34241524-A49C4C22-610B-44FD-80F3-3BB16C65AC27Q34676424-7506C70F-4010-402F-992D-B0B7868270FAQ34768322-288BB019-9308-47FE-AC4D-9A1BD639189FQ34784692-0E5968A5-FCDE-4E9E-AC6D-0CC982F33141Q35110426-0E1316A0-717F-49A4-B8D7-EE548401D924Q35135394-A3F59AA8-9B3F-4850-B6F4-E51C8602B9EBQ35626083-DD26E2D0-0BFA-4EE4-A812-590561D7E672Q36067020-332E0124-B841-4578-B5F1-A7576F1F8162Q36088154-8371C1D2-DAAA-4B3D-8953-FB2BFE1DD857Q36180150-3A8FC5D9-5AC4-40AF-BE1D-6C89449502B7Q36282692-4429A306-C88E-41DD-A826-2B4FD29026A0Q36550830-0147F047-2CA6-43C0-84C5-6A5982470EB6Q37038709-3FDF9AA7-D555-46F4-9B68-15622CF31E77Q37038947-6193A10C-AE9D-4447-A175-867DBFDF99F4Q37129567-50817A0E-8350-4303-808E-B0D50998C130Q37138920-970C3392-E360-47F9-9092-85A96F52DBA4Q37200514-E9278B7D-CF14-4233-B573-AA1A4588D992Q37214190-2F024470-AE0C-48BB-855A-9DACA55B9EF5Q37238298-CDA2472B-AB88-4E52-BC8F-0A77DFC5CEB5Q37400759-06F5A6F0-C169-4A48-9F56-AAC5065B0186Q37794503-2DEC8383-8FD0-43CA-869F-B8F3E6306A7FQ38042555-531CEF12-0FF7-418B-A4D5-3374B93F78EBQ38044304-0DC8DCF8-EB34-4A4B-934A-C9F574733345Q38509926-2023AD76-E0A3-4ADD-A758-F1561CD81385Q38917014-6FCCA6A3-AF1D-4AD2-981F-20A37B2C523AQ39783488-2304DBB5-5F57-4B94-B6CF-C27B404EC365Q42634564-F65AEE9A-771C-4C94-B116-3EB9B7C81C57Q42957610-580832CF-0E09-4B62-AF5B-B22A4471402CQ44185515-86E2D6C1-8C30-4F21-B1E8-9C74D27C6D2AQ44429121-81DD25AF-A201-4EDC-B2A3-DF10975C11C2Q46167724-A5061A30-934B-4FD9-A4C2-9EAC1DAE3BBAQ48095229-3FDB648E-7892-4CA1-AB86-724D7BCEA3F4Q49828823-44A86A02-269A-4F22-98BE-730BDB3B255CQ51153714-FA0DEE74-436E-475A-8249-50A6EA54BB25
P2860
Progression of heart failure: a role for interstitial fibrosis.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Progression of heart failure: a role for interstitial fibrosis.
@en
type
label
Progression of heart failure: a role for interstitial fibrosis.
@en
prefLabel
Progression of heart failure: a role for interstitial fibrosis.
@en
P2093
P356
P1476
Progression of heart failure: a role for interstitial fibrosis.
@en
P2093
P2888
P356
10.1007/BF00944780
P577
1995-06-01T00:00:00Z